A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination
with pembrolizumab in patients with advanced solid tumors.